The life of a biotech company can be short\u2014and if it appears on the fast-spinning takeover radar of Novartis, it may be shorter still. That is the case for Excellergy, which only drew wider attention in mid-October with a $70m Series A financing round\u2014apparently also catching the eye at Novartis headquarters in Basel.<\/p>\n
The Swiss pharma group is thus pressing ahead with its buying spree in innovative medicines, once again focusing on immunology. With the planned acquisition of Excellergy, Novartis secures a promising early-stage programme targeting allergic diseases. The deal is valued at up to $2bn, including upfront and milestone payments.<\/p>\n
Trifunctional approach to immunoglobulin E<\/p>\n
At the centre is the antibody candidate Exl-111, currently in Phase I trials. Unlike existing therapies, it not only targets free circulating immunoglobulin E (IgE) but is also designed to detach IgE already bound to immune cells, potentially enabling faster and deeper suppression of allergic signalling pathways. These pathways play a key role in conditions such as food allergies, chronic urticaria and allergic asthma.<\/p>\n
Strategically, Novartis is building on its blockbuster Xolair, which also targets the IgE pathway but is likely to face biosimilar competition in the future. Exl-111 is conceived as a next-generation extension of this validated mechanism and could complement the existing allergy portfolio, both in terms of efficacy and convenience.<\/p>\n
Novartis stays on a shopping spree<\/p>\n
The transaction also underlines the Basel-based group\u2019s consistent expansion strategy. In recent months, Novartis has struck a series of deals to broaden its pipeline and gain access to innovative platforms and early clinical programmes, with a particular focus on high-growth therapeutic areas such as immunology, oncology and gene therapy. Hardly a week goes by without the company announcing a new partnership or acquisition.<\/p>\n
Last year alone, Novartis spent an estimated $17\u201318bn on acquisitions (dominated by the takeover of Avidity), with additional collaboration and licensing deals potentially adding another $10\u201315bn in milestone payments. In total, external pipeline expansion amounted to around $30bn. This trajectory has continued into the current year, including a billion-dollar-plus collaboration with Unnatural Products and an asset deal with Synnovation Therapeutics that could reach up to $3bn.<\/p>\n
With the Excellergy acquisition, Novartis is following this established pattern while also sending a clear signal: rather than focusing on late-stage, high-cost product acquisitions, the company is increasingly targeting differentiated technologies and mechanisms of action at earlier stages of development. The aim is to secure long-term competitive advantages\u2014particularly in markets where established blockbusters are coming under pressure from follow-on products.<\/p>\n
Whether it will ultimately succeed in advancing this \u201cbouquet\u201d of acquired assets\u2014often based on very different scientific approaches and lacking a clear molecular connection, united primarily by their promising efficacy profiles\u2014within a single organisational and clinical development framework remains uncertain. What currently appears to be a prudent strategy to mitigate the looming patent cliff could, in hindsight, resemble a scattergun buying spree if only a fraction of these programmes reach the finish line. A definitive judgement, however, is unlikely to be possible for another decade.<\/p>\n","protected":false},"excerpt":{"rendered":"The life of a biotech company can be short\u2014and if it appears on the fast-spinning takeover radar of…\n","protected":false},"author":2,"featured_media":41441,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[127],"tags":[3264,23188,1664,24027,24028,206,17],"class_list":{"0":"post-41440","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novartis","8":"tag-acquisition","9":"tag-allergy","10":"tag-antibody","11":"tag-asthma","12":"tag-ige","13":"tag-novartis","14":"tag-switzerland"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116317504592826505","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/41440","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=41440"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/41440\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/41441"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=41440"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=41440"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=41440"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}